RxDoctor Payments Data

Jeffry Rocker, DO

Family Medicine · Oviedo, FLNPI 1013997683

Payments from drug & device makers

$4,583in general payments, 2019–2025

Across 275 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$452
  • Novo Nordisk$426
  • Merck$349
  • Lilly USA, LLC$321
  • Amgen$302
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$4,48298%
  • Education$1012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,583 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$160,516
Medicare patients
427
Services billed
3,486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$41,643
EliquisApixaban27$20,894
JardianceEmpagliflozin27$18,472
FarxigaDapagliflozin Propanediol24$16,583
XareltoRivaroxaban18$13,344
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$6,156
Tresiba Flextouch U-100Insulin Degludec11$4,104
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen67$2,219
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen93$2,086
Ezetimibe54$1,891
Testosterone Cypionate67$1,804
Rosuvastatin Calcium143$1,517
Nebivolol Hcl19$1,436
Ascomp With CodeineCodeine/Butalbital/Asa/Caffein12$1,414
SynthroidLevothyroxine Sodium16$1,371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$426$41,64343 claims
PfizerEliquis$276$20,89427 claims
Boehringer IngelheimJardiance$144$18,47227 claims
AstraZenecaFarxiga$452$16,58324 claims
Johnson & JohnsonXarelto$112$13,34418 claims
GSKTrelegy Ellipta$210$6,15612 claims
AbbVieSynthroid$1,241$1,37116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Oviedo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →